Camu camu and its applications in nutraceutics

The Amazonian forests are home to a shrub, the camu-camu, whose fruit could be of great help in the fight against obesity and metabolic diseases

This is described in our latest study published with the A-Mansia R&D team in the journal Metabolites.

Overweight, obesity, and their comorbidities are currently considered a major public health concern

Today considerable efforts are still needed to develop efficient strategies able to attenuate the burden of these diseases. Nutritional interventions, some with plant extracts, present promising health benefits.

In this study, we evaluated the action of Camu-Camu (Myrciaria dubia), an Amazonian fruit rich in polyphenols and vitamin C, on the prevention of obesity and associated disorders in mice and the abundance of Akkermansia muciniphila in both cecum and feces.

Methods :

We investigated the dose-response effects of Camu-Camu extract (CCE) in the context of high-fat-diet (HFD)-induced obesity. After 5 weeks of supplementation, we demonstrated that the two doses of CCE differently improved glucose and lipid homeostasis.

Results :

The lowest CCE dose (62.5 mg/kg) preferentially decreased non-HDL cholesterol and free fatty acids (FFA) and increased the abundance of A. muciniphila without affecting liver metabolism, while only the highest dose of CCE (200 mg/kg) prevented excessive body weight gain, fat mass gain, and hepatic steatosis. Both doses decreased fasting hyperglycemia induced by HFD. In conclusion, the use of plant extracts, and particularly CCE, may represent an additional option in the support of weight management strategies and glucose homeostasis alteration by mechanisms likely independent from the modulation of A. muciniphila abundance.

 Source : Abot A, Brochot A, Pomié N, Wemelle E, Druart C, Régnier M, Delzenne NM, de Vos WM, Knauf C, Cani PD. Camu-Camu Reduces Obesity and Improves Diabetic Profiles of Obese and Diabetic Mice: A Dose-Ranging Study. Metabolites. 2022 Mar 29;12(4):301. doi: 10.3390/metabo12040301. PMID: 35448490; PMCID: PMC9025096.











Enteric neurons for functional applications in health care

Pharmaceuticals Studying the role of the Enteric Nervous System (ENS) in the development of gut-brain pathologies (e.g., Alzheimer’s, Parkinson’s, diabetes, aging, stress, visceral pain) is an ever-expanding research topic. Researchers are starting to propose numerous...

Enteric neurons and glycemia control

The gut-brain axis:You have a message from your gut In the intestine, gut distension and nutrients are detected by mechanoreceptors and chemoreceptors, respectively. The activation of these receptors sends an afferent nervous message to the hypothalamus in the brain....

The enteric nervous system is our second brain

  The enteric nervous system (ENS), referred to as the “second brain,” is an extensive network of different cell types located along the digestive tract. It consists in enteric neurons, enteric glial cells and interstitial cells of Cajal. This network of cells is...

Enterosys participates in Biofit 2022 in Strasbourg

With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing...

Enterosys will attend NutrEvent 2022 in Nantes

NutrEvent is the event dedicated to innovation in Food, Feed, Nutrition and Health. This year, NutrEvent is back for its 8th edition in a hybrid format. This hybrid event will be held both in-person and online. Enterosys will be present with a validated, complete and...